Company rngl$tr•tlon numb•r 094812091England and W¥l•$l Charity regi¥tr&tion number 1163743 {England and W•lè81 UK FORUM ON HAEMOGLOBIN DISORDERS ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
UK FORUM ON HAEMOGLOBIN DISORDERS LEGAL AND ADMINISTRATIVE INFORMATION Tru8ts•¥ Dr Mary Pglrou ITrgasuror) Dr Rachel Kesse-Adu Dr Subama Chakravoty DrA Luqmani Di R Andgrson A Bla¢kniore Ch•rfty number 1163743 ComnY numb•r 09481209 Regl8tsred offlcè Galla House 695 Hi9h Road Norih Finthley London N1208T A¢eountsnts Lyon8 Lèonidou Galla House 695 High Road North Finchlay London N1208T Bank•rn National Westminster Bank PIC Queen Street Bran¢h 96 Queen Street Cardrfr CF10 2GR
UK FORUM ON HAEMOGLOBIN DISORDERS CONTENTS Pago Trustegs, report A¢eountsnts' report Statement of flnanclal actlvltle8 Balanco Sheet Notes lo the fin8nd&l statemènts 8-13
UK FORUM ON HAEMOGLOBIN DISORDERS TRUSTEES. REPORT (INCLUDING DIRECTORS, REPORT) FOR THE YEAR ENDED 31 MARCH 2025 The trustee5 {who are also director8 of the th8rity for th& purposes of the Companlès Act) present Ihelr report and aUnIS for the year ended 31 March 2025. The aeuunts have beèn prepared in accordanc& with the accounting poIleS Sel out in note 110 the aco)unls and comply wtth tha chariV5 govarnlng docurnenl. the Companies Act 2006 and the Sl8t¢m¢nl of R8commonded Practic8. 'Accounling and Reporting by Chartties" issuod in March 2005. Obl•cilv•• and a¢tlvltl Tha char'ty's objects ar8 specifically restricted lo the adv8ncemenl of health for the public benefit by promoting care for Ihoso with haemoglobin disorders and study and research In haèmoglobin disorders and the publlcalion of useful resutts. Tha chaTty will continue to provide peer review and condud cours&$ for the odvancemenl ol thè health professlon on the sublect of thg blood disorders, sickle cell dlsea5e and thalassaemla. The Iruslees have paid due regard to guldan¢e18sued by the Charty Commission in deciding what aclivilias the ohartly should undertake. The charty undertook Ihe following activtties.. Peer R•vlew The UKFHD conldbuted £45,000 and VAT towards the wsts of the peer review program led by Dr Emma Dralar. which commenced on 17th October 2024 al Sheffield Teaching Hospital NHS Foundation Trust. and Is due lo be completed with a fin81 M$il on 12th September 2025 al Barkbng 8nd Havering NHS Foundallon Tru51s al Queens Hospital Sn Romford. R&viow aim$ lo attend all SHTS and HCCS in England. Host Trust$ are diredly invoiced for the remainder of the costs of th8 r•view including SUPPOrt for clinical leads to wrfte Ihe peer revlew reports, al £5,900 per stsmce. For each v63il. thè le•W teams complete a pr8-wsi¢ review of submitted evidence from the $pecialSs1 haemoglobinopalhy and coordinating centre teams. This gvidenca assessment is completed virtualty. bèforè tha physical visit to the Hospital silè Ss undertaken. The adminislralionllogistic support for the peer review programme was ujnlracted lo, and is undertaken by an external company. NHS Mldlands and Lancashire, led by Ms Sarah Brctimhead, Professlonal Lead for Nursing and Urgent Care Dbrectorale. Educatlonal m8•tSngs We continued lo organi$e 2 academic meetings per year, In 2024 these were h&ld'. 8th May 2024, the 5Ph Educational meeting was hgld at the IET in Birmingharn, this was originally planned lo be an in person *Jnly meetbng bul then had lo be ¢h8nged last minute lo a hybrid meetlng due lo Industrlal action gn the railways. The meeting was org8nSsed, as usual in partnership with the Hartley Taylor team LTD1040293001. The mornlng sessions focu8èd on a case presentation from a resident doctor colleagu&, thgn a tslk on gene therapy from Prof de la Fuenle ol Imperial Colltrg&, London, followed by a talk on fertility presÈNalion by Dr Vikram Talaulikar of UCH London. Then we had a vibrant and inleraetive round table with transplant coll8agug5-, Dr Ben Carpèntar. Dr Bgki Jame$ and Dr Subarna Chakravorty, as well as rèd cell colleagues Dr Amy Webster, and Dr P&rla EWth&rfoy and Ms Roanna Maharaj as a palbènl represenlalive. The round table focused on the ¢urrenl pathways for curative Iheraplas and gene Ihwapy, indicallons, concorns and outcome. There was an update from tho pallent soci8lle$ and the aftemoon session chaiied by Dr Kata Gardner focused on ageing In haemogloblnop8thies, wllh talks from Dr Shivan PanGham, Dr Kale Gardner, Psychologist Dr Ruth Anderson and Fraity physiclan Dr Huma Naqvl from Blmiingham and Sanolvell Hospitals.
UK FORUM ON HAEMOGLOBIN DISORDERS TRUSTEES. REPORT (CONTINUEDI{INCLUDING DIRECTORS, REPORT) FOR THE YEAR ENDED 31 MARCH 2025 19m Nov 2024.. Tha 58th Educauonal meeting wa8 8 hybrid meelSng vllh In person and a virtual audience, we continued the su¢ce¥sful In partnership with the Hartley Taylor team LTD and the meeting was held at Ihe Cavendi8h Conference cenlre. The mornin9 session chaired by Dr M8ry Petrou had an update from colleagues in Scotland on haemogloblnopathy Iherg. wo celebrated colleague5 who have left tha NHS. Or Samah Babiker presented for Prof Inu8a whts has retired and moved into industry, Dr Clare Samue180n presented on behaw of Dr Josh Vvrighl and Dr Emma Drasar on bahaif of Df Farrukh Shah who was the preceding Chaii of the UK Forum. Thore were also présontations on the role of dielelics from Dr C18udin8 Matthes, Endocrinology in Th818gsaem58 by Dr Julian W8ung. The afternoon sessions had presentslions from Prof Noemi Roy on NEQAS, then we focused on strokes In adults wilh pre$gnl8lion$ by Dr Paul Holmes, Dr Anupama KrSshnamoorthi la case study} and Mr Cristo8 Toll88. Then we conduded wrth a CRG update and the launch of the new RCN Nursing competencles. There was an additional symposium from Vertex on Gene Therapy. whlch members could elect lo slay on lor at the dose of ihe day, Both academic me&llng8 had engagement from more than 100 att8ndee8 wllh excellent f99dback, Tru•tee and committee m?etings After November 2024. wè moved iwo of the trustee and committee meetings lo coincide with tha educational meetings. aiming to encourag8 in peison ¥ttendance, theso wero sChedud in the hour preceding the a¢ad8mic meetings. Additional committee rneelings over MSToams warè held in June, and September 2024. Liai80n and attendancg whh other MMItto$ (feedback lo Trustee5 via rolllng agenda NatSonal Screenlng Cornmitt88.' we had new members joining tho committee for the antenatsl and n&onatal scr8&nin9 programm8 for ha8moglobinopalhies. National Haemogloblnopalhy Registry.. Prof Noemi Roy was added to attendarKe after departurg ol Dr Farrukh Shah lo support Ihe work ofthe NHR. Cllnicgl Rgfgr9nce Group for Haemoglobinopalhies- Dr Subama Chartoravoty who is a trustee a3 wtrll 8s tha CRG th8ir r8pr8sented the CRG to update on the work of th81 group. We added regular reproSgn¢alion from colleagues from ScollJnd - Dr Fèrnando Pinlo and Dr Loulsa Mclllwaine, we had conllnued repiesenlallon from Wales with Dr Indu Thakur and Ms Annattg Blackmore. Northem Ireland reprè8entalion from Colleen Wlliamson Rgsearch Th• red cell rAJllaborative resear¢h group was orlginally represented by Dr Paul Teffer, however his attendance tailed off after his resignauon from the commmee as a trustee. a new m8rnber- Dr S8nne Lugthart was co-OPt•d to kegp Ihe mmittee updated. Achievements and perforniarbcè We remained a key stske holder for NICE submissions and were actlvely Involved In th8 ullirnalely successlul, Casgevy submls8ion8 for both 8k19 cell and Thalassaemla. We appointed a lead clinidan and conllnued lo support the organisalSon, implemenlallon and acilve Involvement of lh¢ clinlcal community in the haemo9lobinopathlas p8•r review program. Wa COnnUed to hold the IwIce-ye¥ 8cadgmio sessions whickn have both eXlIent alt•ndance and feedba¢k as notad above, tOPiC8 are selectsd from a combination of issues raised the NHP and from attendee feedback. We $tOrted an initiative lo extend invitation to Iralnoas tha attend our Edu¢alion days fraa of charge lo encourage inlarest in the field.
UK FORUM ON HAEMOGLOBIN DISORDERS TRUSTEES. REPORT (CONTINUED)(INCLUDING DIRECTORS, REPORT) FOR THE YEAR ENDED 31 MARCH 2025 Flnanclal r•vlow The prinupal source of fundlng Is from voluntary donatlons from individual and other organ18altons. The prinpaI source of fundlng is from applications for independent fundlnu grants from industry partners aimed 81 our educallon day8, voluntary donatlons and rnambership dues. It is tha policy of the charity that unreslrfcled funds whlch h8ve not been deslgnaled for a spedflc use should be malnl?Ined 81 a18val equivalent lo betsyeen three and six-monlh's expendilure. The trustees conslder that roserves at Ihls l&vg1 will ensur& Ihal. in the event of 8 significant drop in funding, they will be able lo continue the ¢harily'8 Current 8Ctlvltl68 whlle oonslderation Is 9iven lo ways in whlch adOnal fvnd$ may be raised. Thi¥1gvel of reserve5 has boen malntained throughout the year. Tha truslaas havè ass8ssed the major risks lo which the charity is exposed. and are satisfied that systems aro in place lo mitlgala exp05uro to Iha major risks. The tharity will continue to me81 the objectives of 11$ ¢on$Utulion. The tru8te&s hgve assess8d the maSor risks lo whith the charlty Is exposed, and are satisfied that systems are in place lo rnitigale exposure to Ihg major risks. The charty will contsnue to meet the obledv88 of ils conslKulion. 11 will also ty lo increase the Incoming lev81 of donalon.
UK FORUM ON HAEMOGLOBIN DISORDERS TRUSTEES, REPORT (CONTINUED)(INCLUDING DIRECTORS. REPORT) FOR THE YEAR ENDED 31 MARCH 2025 Struciuro. governanc• and manag•m•nt The charity is a ¢omp8ny1Smltèd by guarantee. Incorporaled on 10th March 2015 and r•gisl&red as charity on 28th September 2015 whh Reglsl&rèd Charity No 11633743. The company was èstablished under Memorandum of AssocAatSon. whlch established the objects and powers of the charitable company and is govemed under ils Artlcles ofAs$oryalion. Dr Femando Pinto and Dr Loulsa Mcllwaine hav8 joined committee 8s repr9senlalives of Scotland. The Irusl8gs gnd who sarvgd durfn9 the year and sub8equenUy were.. Dr Mary Pelrou (Treasurer) Dr Farrukh Shah Dr Rad)el Kes$evAdu Dr Subama Chakravoty DrA Luqmani Dr R Andar$on A Blad(more (Resigned 28ApTiI 2024 The trustees are seleded for their understanding and sympathy with the airn and objectivès of the oharity, and have ¢onflm)¢d they aro prepared lo offer th8ir time and expertise lo support it. Non8 ofthe twstees has 8ny beneficlal int8rg$t in tho company. All ofthe Irusle$$ ara rn8mb8rs of the company and guarantee lo contribute £1 in event of a winding up. The tharty doè8 not providè the trustees wtth any indemnlty Insurance. Th& Iruslees me¥1 on a ragular basis to agree the slralegS¢ diieclion and the policy of the Charity. Ong of the Iru51ee Is responslble for the day lo day admlnlslration lo ensure that the charfty oan deliver tirnely and elfi¢l&nl service. Thgrg aro no nnectfjd charitiès. The Iru818es' port Was approved by the Board ol Trustees. Dr Mary Petrou (Trea Trustee Dated.. 12 March 2026 urgr)
UK FORUM ON HAEMOGLOBIN DISORDERS CHARTERED ACCOUNTANT ACCOUNTANTS, REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF UK FORUM ON HAEMOGLOBIN DISORDERS FOR THE YEAR ENDED 31 MARCH 2025 In order lo assist you to futfil your duties under the Companies Act 2006, we have prepared for your approval the nancial statements of UK Forum on Haemoglobln Disorders for the year ended 31 March 2025, whlch comprlse the slalomenl of financial activities and the related notes from the charity's accounllng ro¢ords and from infomiation and explanations you have given us. As a praclislng m&mb8r firm of the Inslilut8 ol Charterad Accountants in England and Wales, we are subje¢t lo 51$ elhlcal and olhef professlonal requlremenls whlch are detsiled al https.'1Ww.Icaew.GoMlreg1aknOn. This report is made lo the ¢harlty's Iwslees, a$ a body, in accordanc£ wilh the temis of our engagement lètter. Our work has been undertaken solely to Prepare for your 8pproval the accounts of UK Forum on Haemoglobin Disorders and stale those matters that we have agreed to 8tale lo the charity's trustees, as a body, in this rgport in accordanca with ICAEW Tachnical Release 07116. To the fulle81 extent pemilled by law, we do not aecepl or assume responslbillty lo anyone other than UK Forum on Haemoglobin Di50rders and the charlty's trustees as 8 body, for our woth or for thls report. 11 is your duty lo ensuré that UK Forum on H8èmoglobin Disor(lers ha$ kept ad¢quate acLounting records and lo prepare slalulory financial slaternenls that give a true and fair vlew of thè assèts. liabilities, financial position and deficAI of UK Forum on Haemoglobin Dlsorders. You conslder that UK Forum on Ha8moglobln Dlsorders Is exempt fr¢)m the slalutc¥y audit roquiremenl for the year. and is not required to obtain an In¢Jop&ndent •xamin&rfs r¢port. Wg havg riot been inslruded lo carry out an audit or a rewew ol the financial ststemenls of UK Forum on Haemoglobin Disorders. For this reason, we have not verified the accuracy or ¢omplelenes8 of the accounllng racords or information and 8xpl8ng1Sons you hav9 glven to us and w8 do not, therefore, express any opinion on the slalutory flnan¢lal slalgmenls. Lyons Leonldou Charternd A¢¢ountsnt Ac¢ountsnts 13 March 2026 Galla Hou8e 695 High Road North Finchloy London N120BT
UK FORUM ON HAEMOGLOBIN DISORDERS STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2025 Unr•8trlctod Restrl¢ted funds funds 2025 202S Total Unrestrlcted Ro$trf¢ted funds lunds 2024 2024 Total 2025 2024 Noto• Income from: Donatlons and lagacias Charitabl8 acliwlies Investments 2.629 38.SC 161 2.629 38.500 1,150 42,844 151 1,150 42.844 151 Tot41 Incomg 41,290 41,290 44.145 44,145 Expenditure on: Charitable actlvNle8 48,582 27,000 73,582 49,246 27.000 76,246 Total èxpèndltur• 46,582 27.000 73,582 49,246 27,000 78.246 Net •xp•ndlturn 15.2921 127,000) 132.2921 15.1011 127,000} 132,1011 Transfer8 belweèn funds 156.8501 50.650 Net movem•nt In funds 181.942} 29,650 {32,2921 15,101) 127,000} {32,1011 Reconclllatlon of fund•: Fund balances al 1 Aprll 2024 158.898 99,505 2S8,403 163,999 126,505 290.504 Fund balanc•s at 31 reh 2025 96,956 129,155 226.111 158,898 99.505 258,403 Th& stslement of financial acliMlie8 includès all galns 8nd losses recognised in Ihe year. All Income and expendfture derfve from continulng 8Ctivllles.
UK FORUM ON HAEMOGLOBIN DISORDERS BALANCE SHEET AS Af31 MARCH 2025 2025 2024 Not•$ Curr•nt assets Cash al bank and in hand 228,307 260,599 Cr•dltors: amounts falling due wlthln on• yoar 11 12,1961 12,196} N•t curr•nt as#èt# 226,111 258,403 Th• funds of th• charlty Reslricled income funds Unreslrlcled funds 12 13 129,155 96,956 99,505 158,698 226.111 256,403 The company 13 ented to the exemptlon from the audit r8quirernenl contained In sedion 477 of the Companies Act 20C6. for the year ended 31 March 2025. The directors acknowledge their iespon8ibllrtles for complying with the requirèments of the Companies Act 2006 wrth respect to accounlang records and the prèparallon of fin3n¢ial statements. Thè members have not rèquired the company to oblaln an audit of hs finandal slal&ments for the year In question In accordance with sectlon 476. These fin8nrial 81olements have been prepared h accordance wKh the provisions applicable to companle$ Sublgct lo the sm811 companles rgglme. Th8 ffinancial stslemen18 were approved by the Iru51e8s on 12 March 2028 Dr Mary Petrou ITreasurerl Tru$ts•
UK FORUM ON HAEMOGLOBIN DISORDERS NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025 AKountlng pollcl•# Ch*rfty Infomiatlon UK Forum on Ha8moglobin Disorders 15 a private cornpany Ilmited by 9uaranlee Incorpo(8lfjd in England and dl68. Th& regisleied officg is Galla House, 695 High Road, North Finchlgy. London, N12 OBT. 1.1 Accountlng conventlon The finan¢Sal 8lalements have been prepad in a¢eordanc8 with Ihe tharitys governing document, th& Companies Act 2006, FRS 102 'Thg Financial Reporting Standard applicablè in the UK and Republic of Ir81and" and the Charities SORP "Accounting and Reporting by Ch8rf(ies'. Statement of Recomrnended Practice applicable to char5tle5 preparing Ihelr accounts in accordance wrth the FSnan¢Sal Reporting Standard applicable In the UK and Republic ol Ireland (FRS 102}'. The charity is a Public Benefit Entity as defined by FRS 102. Th8 charity has taken advantsge of the provisions in the SORP for charities not to prepare a statement of cash ftows. The finandal statements ar8 prepared in slerfing. whlch is the fijncilonal currency ol thè charity. Monatary amounts In these financlal slatemants are rounded lo the nearest £. The financial statements have been prepared under Ihe historical cost convention, Imodified lo includts the revaluatlon of freehold prop8rties and lo Include invgslmgnt properties and certain ffinanaal instruments at fair Val]. The prinapal accounting policie8 adopted a sel out below. 1.2 Golng con¢•rn Al the lime of approvlng th& flnanclal slatemgnts. the tru51ees have a reason8blg gxpodalion that the charity ha5 adequate resources to continue In operational existence for the forèséeabla future. Thus the tru8lee8 continue to adopt the going concem basls of accounting in preparing the financial stat&menls. 1J Charitable fund¥ Unreslri¢ted funds are available for use al the discretion of Iha trustees in fijrtherancè of IheSr charitable obje8. Re51ricled funds are subject to specifiG conditions by donors a8 to how th8y may be used. The purposes and uses of the restrtcted funds ar6 86t out In the notes to the accounts. Endowment funds ar• sublact to specific conditi'ons by donors that the Capital must be maintslned by thè charity. 1A In¢omlng r•8ources Incom• is recognised when the charity is legally entitlèd lo it after any perform8rKe ¢ondlli¢)ns have been mel. the amoun1$ can be measured reliably, and il is probable that Incomg will be received. Cash donations are recognised on re¢elpl. Olhof donations are racognised once thè charity has been nolffied ol the donation, unless performance eonditions requlre daferral of the amount. Income tax rerovgrable in rolation lo donations reraved under Gift Aid or deed$ of ¢ownanl is recognised al the lime of thè donation. Legacies are recognlsed on receipt or otherwise if the charity has been nolifigd ol an Impending dislribulion, the amount is kntswn, and re¢elpl Is èxpècted. If the amount is not known, the legacy is Iated as a conllngenl a88el.
UK FORUM ON HAEMOGLOBIN DISORDERS NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 Accounting poll¢ie* Icontlnuedl 1.5 Re¥ources expended Resources expended on charitable expenditure comprise In meetlng the charitsble objodive. Such cost ncludes dlrfjct cost of the Charitablo acliwti85 togother wrth those identifiable 8UPPOrt cost in¢urrad that enabl& these activllles lo be undert8ken. Govemance c051 and support cost are COBI inCurd for the man89om•nt and adminislralion of the Charty. These cost are incurred 80 that the Charlty can operate and meet 118 slalulory and constitutional obligatlon. Support cost is 8llocated where appropriate to an activity based on use of iesouroe. Staff cost wher8 appropriate has been allocatgd on 8 n55$1¢nI bas15. 1.6 Cajh and ¢a¥h gqulvalents Cash and cash equivalents Include cash In hand, deposits held al call with banks, other short.lèm liquid invesbments wlth orlginal maturities ol three months or16ss, and bank overdrafts. Bank overdrafts are shown wilhln borrowlngs In current liabilrtigs. Baslc flnanclal assets Basic flnanclal assets, whlch Include (leblors and cash and bank balances, ar8 Iriitially rneasured al Iransaction price induding Iransa¢lK)n 51$ and are subsèquentty carried al amortised cost using the effective Interè51 method unle88 the arrangement conslilules a financing transaction, where the transaction is measured at the present value of the future receip15 discounted at a market rate of interesL Financial assets classified as receivable within one year are not arnortlsed. Basic financial liabilities Ba8ic financlal Ilabllllles, Indudlng creditors and bank loans are inltlally rocognised al transaction price unless the arrangement conslilules a fin8n¢ing Ir8ns8¢1ion. whère the debt instrument is measured al the present value of the future payrnenls d15counled al a market r810 of Interest. Flnancial liabilities classified as payable within one year are not amortised. Debt in51rum6n18 are 8ubs6quenlly carried al amortlsed Cost, uslng Ihg effg¢tlv¢ inlergsl ra18 method. Trade creditors are obligations lo pay for goods or services that have beon acqulred in the ordinary rA)vrse of QP9railon$ from 5uppllers. Amounts payable are classified as current liabilities il payment Is due within one year or less. If not, Ih8y arè prèsènt8d as non-currenl liabilities. Trade creditor8 are recogni5ed initially al transactlon prlce and 8ub8equenlly measured 81 amortlsed $1 using tho effeotive interest method. Derecognltlon of Ilnanclal Ilabllttl Financial liabllsues are derecognised when the charivs contractual obligations expire or are discharged or Cancelled. 1.7 Genernl Fund• Gen6181 funds are unr&strlcted funds whlch are available for use at the discretion of the Trustees lo further the objectives of the Charty. Invgslmenl income and gains are allo¢algd lo unrgslrielad fvnds.
UK FORUM ON HAEMOGLOBIN DISORDERS NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 crftIGal aGcountlng •stlmates and judgements In the application of the Charit6 8c¢ountlng polldes, the trustees ale required lo make judgements, esllmales and assurnpllons about the carrwng amount of assets and nabS1ilies that aro not readily apparent frorn other sources. The estlmales and assodaled assumplions are based on hislorfcal experience and other factors that are nSIdered to b& relevanl. Aclual $71$ may differ from the8e estimates. The e8M81?$ and underfylng assumptions are reviewed on an ongobng basis. Revlsions lo a¢Unting e51imale8 are recognised In the per6od In whlch th& asllmale Is reised where the re$lOn affocls only that Period, or in the period of the rewslon and future poriods wheTa the revision affe¢t8 both Current and future periods. Donadonfj and $ub•¢rlptlono 2025 2024 Membership fees 2,629 1,150 2.629 1,150 Income from ¢h*rltabl• actlvlil•• Unr•¥trfct8d funds 202S Unrestrlcted fund• 2024 Headlng #ac989 Sale of goods 38.500 42.844 Incom• from Inv•stm•nts Unrnstrlcted Unr•strTctod fund8 funds 2025 2024 IntereBI receivable 161 151 10-
UK FORUM ON HAEMOGLOBIN DISORDERS NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 Exp•ndlturo on ¢harltablo a¢lfvltlè 2026 2024 Direct costs Course costs- Hlrlng hall. ¢al$ring and lecturers lees 70,777 73,838 Sharn of lupport and govomanc• co•ts nots 71 Governance 2.805 2,408 73,582 76,246 Analy•i• by fund Unieslricted funds Reslricied lunds 46,582 27.C(KJ 49,246 27,000 73,582 76.246 Support cost8 Support GoYmaneè costs costs 2025 2024 Legal and professional General expense 2,198 609 2,196 609 2,1g6 212 2,805 2,805 2,408 Analysed bofvleen Charitabl8 activities 2,805 2,805 2.408 Govemance costs Includes AcUntan¢Y foes of £2,196 (2022 £2,125). Tru•tse* None of the trustees lor 8ny persons connected with them) re¢elved any remun8ratlon dung the yeai or prevlou& year. None of the tru8te&s were relmbursgd any expgn$g8 durfng rrent year or prevlous year. 11
UK FORUM ON HAEMOGLOBIN DISORDERS NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 Employoos The average monthly number of employ88s durfng the y88r wa8.. 2025 Number 2024 Number There wore no pald employges In the year, 10 Taxatlon The Charfty Is exempl from tsxatlon on Its actlvhiès because all Income Is applied for tharilable purposes. 11 Crèdltors: amcwnts falllng due wlthln yr 2026 2024 Accruals 2,190 2.196 12 R•strletsd funds The income funds of the tharity include reslrided fund8 comprising the following unexpended balance$ of donaliong held on truBI for specific purposes.. At 1 April 2024 Resour¢e• •xpended Tran¥fors At 31 March 2025 99,505 {27,0001 58,650 129.155 Pr•vlou• Yr. At 1 Aprll R•$our¢o$ 2023 xpnd•d Tran$f•r$ At 31 March 2024 126,505 {27,0001 99,505 Rgstrictad funds should be appliad for quallly pe&r revlew programme and work on qualrty assurances lor braln vessel s¢ons for chlldron with sickle ¢ell dl$&a$8. 13 UnYo•trlct•d fund* The unrestricted lunds of the ch8rity comprfse the unexp&nded balances of donations and grants whloh arg not subject lo speryfie conditions by donors and grantors as lo how Ihey may be used. These in¢lude designated fund8 whlch have been Bel aside out of unre8lricled funds by the tru51ee5 for speaffic purposes. At 1 Aprfl 2024 Incomlng rgsources R•sources èxpended Tranjfers At 31 March 2025 Genwal funds 158,898 41,290 146,5821 156.6501 ,956 12-
UK FORUM ON HAEMOGLOBIN DISORDERS NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025 13 VnMtrf¢tsd lunds Icontlnu8dl Prnvlou• y•ar: Al 1 Aprfl 2023 In¢omlng r•¥sgur¢•• Resource8 9XPgndod Translers At 31 March 2024 General funds 163.999 44,145 149,2461 158,898 14 An•1* ol 1¥8ets between funds UnrestrScted funds Re•tri¢ted lund¥ TotAI Fund balances at 31 March 2025 are represented by.. Current assets 98,956 129,155 226,111 96,956 129,155 226,111 13